Mazdutide

Metabolic

Also known as IBI362, LY3305677

GLP-1 and glucagon receptor dual agonist, an oxyntomodulin analogue. Approved in China only.

How it works

An oxyntomodulin analogue engineered for weekly dosing. Like survodutide it combines GLP-1 appetite suppression with glucagon-driven energy expenditure.

Subcutaneous

In the body

Half-life

8 days

Time to peak

3 d

90% gone after

26.6 d

Builds up to

2.2×

Steady state after about 40.5 d at once weekly.

Shape of a single dose, modelled as one compartment with first-order absorption. The peak is normalised to 100% because bioavailability and volume of distribution are not published for most of these compounds.

About 8 days. Individual phase 1 cohorts reported anywhere from 147 to over 1000 hours; the very long upper bounds are almost certainly artefacts of sampling only across a 168-hour window.

What happens, and when

0 min, 2 dAbsorbing slowly. Little felt in the first day or two.
2 d, 4 dPeak plasma levels around 72 hours. Gastrointestinal effects cluster here, 3 to 4 days after the injection.
4 d, 7 dDeclining toward the next dose. Roughly 60% of peak remains at day 7.

Doses

2 mg, 6 mgonce weeklyApproved label

Approved in China with a maximum of 6 mg weekly, and a minimum of 5 days between doses. A 9 mg application was accepted for review in November 2025 but is not yet approved.

9 mg, 16 mgonce weeklyClinical trial

Studied but not approved. 9 mg reached 16.7% weight loss over 60 weeks in GLORY-2; a phase 1 escalation went to 16 mg.

GLORY-1 escalation to 6 mg

NCT05607680, phase 3 · 48 weeks total

wk 1, 42 mg4 weeks
wk 5, 84 mg4 weeks
wk 9, 486 mg40 weeks

The most completely specified titration of any unapproved compound here, the registry states each step explicitly.

GLORY-1 escalation to 4 mg

NCT05607680, phase 3 · 48 weeks total

wk 1, 42 mg4 weeks
wk 5, 484 mg44 weeks

Vial sizes

2 mg4 mg6 mg

Commonly treated as good for 30 days refrigerated once reconstituted.

Side effects

Vomiting in 53%, nausea in 47% and diarrhoea in 39% at the 9 mg dose, against a few percent on placebo
Much better tolerated at the approved 4 and 6 mg doses, where discontinuation for adverse events was under 2%
Decreased appetite, abdominal distension

Cautions

Not FDA approved. Glucagon receptor agonism carries the same considerations as survodutide.

Status

Approved in China by the NMPA in June 2025 as Xinermei, at up to 6 mg weekly. Not approved by the FDA.

Sources

Reference information for personal record-keeping. Not medical advice, and not a recommendation to use any of these compounds.